ArticleThe Journal of pharmacology and experimental therapeutics2011
Molecular analysis and structure-activity relationship modeling of the substrate/inhibitor interaction site of plasma membrane monoamine transporter.
Article in The Journal of pharmacology and experimental therapeutics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- The Interaction of Organic Cation Transporters 1-3 and PMAT with Psychoactive Substances.Handbook of experimental pharmacology · 2021Review
- Brain Plasma Membrane Monoamine Transporter in Health and Disease.Handbook of experimental pharmacology · 2021Article
- Molecular Modeling of Drug-Transporter Interactions-An International Transporter Consortium Perspective.Clinical pharmacology and therapeutics · 2018Review
- Potent inhibition of human organic cation transporter 2 (hOCT2) by β-carboline alkaloids.Xenobiotica; the fate of foreign compounds in biological systems · 2017Article
- Equilibrative nucleoside transporters-A review.Nucleosides, nucleotides & nucleic acids · 2017Review
- The plasma membrane monoamine transporter (PMAT): Structure, function, and role in organic cation disposition.Clinical pharmacology and therapeutics · 2016Review
- Polyspecific organic cation transporters and their impact on drug intracellular levels and pharmacodynamics.Pharmacological research · 2016Review
- Potent and Selective Inhibition of Plasma Membrane Monoamine Transporter by HIV Protease Inhibitors.Drug metabolism and disposition: the biological fate of chemicals · 2015Article
- Anatomical and functional evidence for trace amines as unique modulators of locomotor function in the mammalian spinal cord.Frontiers in neural circuits · 2014Article
- Impaired monoamine and organic cation uptake in choroid plexus in mice with targeted disruption of the plasma membrane monoamine transporter (Slc29a4) gene.The Journal of biological chemistry · 2013Article
- Computational modeling to accelerate the identification of substrates and inhibitors for transporters that affect drug disposition.Clinical pharmacology and therapeutics · 2012Article
- Electrophysiological characterization of the polyspecific organic cation transporter plasma membrane monoamine transporter.Drug metabolism and disposition: the biological fate of chemicals · 2012Article
- Expression Profiling of Solute Carrier Gene Families at the Blood-CSF Barrier.Frontiers in pharmacology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Plasma membrane monoamine transporter (PMAT) is a new polyspecific transporter that interacts with a wide range of structurally diverse organic cations. To map the physicochemical descriptors of cationic compounds that allow interaction with PMAT, we systematically analyzed the interactions between PMAT and three series of structural analogs of known organic cation substrates including phenylalkylamines, n-tetraalkylammonium (n-TAA) compounds, and β-carbolines. Our results showed that phenylalkylamines with a distance between the aromatic ring and the positively charged amine nitrogen atom of ∼6.4 Å confer optimal interactions with PMAT, whereas studies with n-TAA compounds revealed an excellent correlation between IC(50) values and hydrophobicity. The five β-carbolines that we tested, which possess a pyridinium-like structure and are structurally related to the neurotoxin 1-methyl-4-phenylpyridinium, inhibited PMAT with high affinity (IC(50) values of 39.1-65.5 μM). Cytotoxicity analysis further showed that cells expressing PMAT are 14- to 15-fold more sensitive to harmalan and norharmanium, suggesting that these two β-carbolines are also transportable substrates of PMAT. We then used computer-aided modeling to generate qualitative and quantitative three-dimensional pharmacophore models on the basis of 23 previously reported and currently identified PMAT inhibitors and noninhibitors. These models are characterized by a hydrogen bond donor and two to three hydrophobic features with distances between the hydrogen bond donor and hydrophobic features ranging between 5.20 and 7.02 Å. The consistency between the mapping results and observed PMAT affinity of a set of test compounds indicates that the models performed well in inhibitor prediction and could be useful for future virtual screening of new PMAT inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.